SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

BACKGROUND: Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targeted have not been identified. Aβ immunotherapy-related vasogenic edema has also...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradier, Laurent, Blanchard-Brégeon, Véronique, Bohme, Andrees, Debeir, Thomas, Menager, Jean, Benoit, Patrick, Barneoud, Pascal, Taupin, Véronique, Bertrand, Philippe, Dugay, Philippe, Cameron, Béatrice, Shi, Yi, Naimi, Souad, Duchesne, Marc, Gagnaire, Marie, Weeden, Tim, Travaline, Tara, Reczek, David, Khiroug, Leonard, Slaoui, Mohamed, Brunel, Pascale, Fukuyama, Hidehiro, Ravetch, Jeffrey, Canton, Thierry, Cohen, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264593/
https://www.ncbi.nlm.nih.gov/pubmed/30486882
http://dx.doi.org/10.1186/s13195-018-0447-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264593/
https://www.ncbi.nlm.nih.gov/pubmed/30486882
http://dx.doi.org/10.1186/s13195-018-0447-y

Ejemplares similares